Stem Cell and Derivatives

IWP L6 (Porcn Inhibitor III) is an extremely effective Porcn inhibitor (EC50: 0.5 nM).

AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).

YAP/TAZ Inhibitor-4 (Compound 45) acts as an inhibitor of YAP/TAZ, exhibiting inhibitory activity on TEAD transcriptional activation by preventing the interaction between YAP or TAZ and TEAD.

Casein kinase 1δ-IN-8 is an inhibitor of casein kinase 1δ and is used to treat neurodegenerative diseases such as Alzheimer's disease type.

NMS-P715 is a highly selective and ATP-competitive MPS1 inhibitor(IC50 of 182 nM).

Cucurbitacin I, cytotoxic triterpenoid sterols isolated from plants, elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/

Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.

Anti-5T4/TPBG Antibody (9P872) is an antibody targeting 5T4/TPBG. Anti-5T4/TPBG Antibody (9P872) can be used in ELISA, FCM.

JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.

WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6

JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32

ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.

STAT6-IN-3 (Compound 18a) serves as an inhibitor of STAT6 with an IC50 value of 44 nM, specifically targeting the Src Homology 2 (SH2) domain.

CCG-232964 is an orally active Rho/MRTF/SRF inhibitor that suppresses LPA-induced CTGF gene expression [1].

LX7101 is an effective inhibitor of LIMK and ROCK2 (IC50: 24, 1.6, and 10 nM for LIMK1, LIMK2, and ROCK2, respectively). It also inhibits PKA (IC50 <1 nM).

Dehydroglyasperin D exhibits anticancer, anti-inflammatory, anti-obesity, antioxidant and anti-aldose reductase effects, it inhibits the proliferation of HT-29

SR-3677 is an effective and specific inhibitor of ROCK2 (IC50: 3 nM).

ZINC00881524 (ROCK inhibitor) is an effective and specific ROCK inhibitor.

ROCK-IN-5 (I-B-37) inhibits kinases like ROCK/ERK/GSK; may aid in cardiac and neuro disease studies.

Stafia-1 is a potent STAT5a inhibitor ( IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.

RhoA-ROCK-IN-1 (Compound b19) is an inhibitor of the RhoA/ROCK pathway. It significantly inhibits cell proliferation, migration, and invasion, while promoting cell apoptosis (apoptosis). RhoA-ROCK-IN-1 exhibits strong anticancer activities by inhibiting the RhoA/ROCK pathway.

JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human ASPP1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human ASPP1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human ASPP1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human ASPP1 in the samples is then determined by comparing the OD of the samples to the standard curve.

G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.

DT-6, a potent TGF-β1 inhibitor, impedes M2 macrophage-induced epithelial-to-mesenchymal transition and the invasive migration of cancer cells, thereby showing

RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays

W1131 TFA is a potent STAT3 inhibitor inducing ferroptosis, effectively halting cancer progression in subcutaneous xenograft, organoid, and PDX models of

CCT251545 is an potent and oral-bioavailable WNT signaling inhibitor(IC50 of 5 nM in 7dF3 cells).

APTSTAT3-9R acetate is a selective peptide binding STAT3 with antiproliferative and antitumor activity.

TP0427736: ALK5 inhibitor, IC50=2.72 nM, 300x > ALK3 selectivity; counters TGF-β in human cells, extends anagen in mice.

JAK-IN-5 hydrochloride is a JAK inhibitor [1].

ETC-159 (ETC-1922159) is a potent, orally available PORCN inhibitor. It inhibits β-catenin reporter activity with an IC50 of 2.9 nM.

Antitumor Agent-73, derived from Diosgenin, blocks STAT3 and activates Pdia3, showing strong cancer cell line efficacy.

Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.

BML-284 (Wnt agonist 1) is a potent, selective and , cell-permeable Wnt signaling activator.

hAChE-IN-5 (compound 49) is a dual inhibitor of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBuChE), exhibiting inhibitory potency with

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human Cys-C, and the Human Cys-C standard plate wells that pre-coated using protein-related techniques are provided separately. Standard/Sample Diluent Buffer or samples are added to the appropriate microtiter plate wells ,then added a HRP-conjugated antibody specific to Human Cys-C. After TMB substrate solution is added, only those wells that contain Human Cys-C and HRP-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Cys-C in the samples is then determined by comparing the OD of the samples to the standard curve.

Blosozumab (LY2541546) is a monoclonal antibody targeting sclerostin that promotes bone formation, used in the research of osteoporosis.

JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,

VP3.15 dihydrobromide: potent, oral, CNS-penetrant PDE7/GSK3 inhibitor; IC50s: PDE7- 1.59 μM, GSK- 0.88 μM.

Ac-ESMD-CHO functions as an inhibitor of both caspase-3 and caspase-7, specifically obstructing the proteolytic cleavage of the caspase-3 precursor peptide (

SD-208 (ALK5 Inhibitor V), a selective TGF-βRI (ALK5) inhibitor (IC50: 48 nM), is >100-fold selectivity over TGF-βRII.

ROCK-IN-8 (Example 4), a ROCK inhibitor, exhibits anti-inflammatory properties and is suitable for respiratory and gastro-intestinal disease research,

Ceftriaxone Sodium is a sporotaxin antibiotic that inhibits GSK3β and Aurora B. It is used in the study of sepsis and infective endocarditis.

Y-9738 is an agent of hypolipidemic.

JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.

Aβ42 agonist-1 is a small molecule compound with anti-cancer activity and NF-κB inhibitory properties, inducing Aβ42 aggregation.

LY2090314, a potent GSK-3α/β blocker (IC50: 1.5/0.9 nM), could boost platinum chemo. Tested in leukemia and advanced cancers.

IM-12, an effective GSK-3β inhibitor(IC50=53 nM), regulates Wnt signalling.

BML-284 hydrochloride (Wnt agonist 1 HCL) is a potent, selective Wnt canonical signaling activator and tubulin polymerization inhibitor.

DAPM (gamma-Secretase Inhibitor XVI) is a Notch pathway inhibitor with anticancer activity and antiproliferative effects.

Anti-SOST Antibody (3R170) is an antibody targeting SOST. Anti-SOST Antibody (3R170) can be used in ELISA, IHC.

XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.

WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.

SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.

JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and

Anti-NANOG Antibody (1M448) is a Mouse antibody targeting NANOG. Anti-NANOG Antibody (1M448) can be used in ELISA, WB, ICC, IF, FCM.

MBM-55S, a Nek2 inhibitor with 1 nM IC50, induces cell cycle arrest and apoptosis, suppressing tumor growth.

AS1517499 is a potent STAT6 inhibitor with IC50 of 21 nM

Anti-GPC3 Antibody (4L576) is an antibody targeting GPC3. Anti-GPC3 Antibody (4L576) can be used in ELISA, WB, IF.

WAY262611 is a Wnt/β-catenin agonist and an inhibitor of Dkk1. It increases bone formation rate with EC50 of 0.63 μM in TCF-luciferase assay.

STAT3-IN-3 is a potent and selective signal transducer inhibitor and transcription 3 (STAT3) activator.

DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).

Wnt-C59 (C59)(C59) is a highly effective and specific Wnt signaling antagonis with PORCN enzymatic activity.

BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.

Glasdegib (PF-04449913) (PF-04449913) is a potent, and orally bioavailable Smoothened (Smo) inhibitor with IC50 of 5 nM. Phase 2.

PF-04802367 is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay.

CCT 031374 hydrobromide is a TCF/β-catenin inhibitor with antitumor activities.

Cotosudil is a ROCK kinase inhibitor with antihypertensive activity used to treat or prevent neurodegenerative diseases.

Hematein blocks Akt/PKB, Wnt signaling, promotes apoptosis in lung cancer, is a dye from hematoxylin, and inhibits casein kinase II (IC50: 0.74 μM).

I3MT-3 (HMPSNE) is a selective inhibitor of 3MST, targeting active site cysteine residues and permeating cell membranes.

Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.

3,5-Bis(4-nitrophenoxy)benzoic acid (Compound W) is an inhibitor of γ-secretase. It decreases the released levels of Aβ42 and notch-1 Aβ-like peptide 25.

CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.

MYF-01-37 (1-[3-Methyl-3-[3-(trifluoromethyl)anilino]pyrrolidin-1-yl]prop-2-en-1-one) is a novel covalent TEAD inhibitor.